Fetal stem cells aim to tame immune chaos
NCT ID NCT03123458
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests clonal fetal mesenchymal stem cells (cfMSCs) in 100 people with severe immune-related disorders or tissue damage. The goal is to see if the cells are safe and can reduce symptoms. Participants have no other treatment options left.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- clonal fetal mesenchymal stem cells (cfMSCs)
- What this could lead to
- If it works, this could offer a new way to control severe immune disorders and reduce symptoms for patients who have no other options.
- What could go wrong
- This is a very early Phase 1 trial, so safety and effectiveness are not yet proven. There may be side effects, and the approach may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, 518000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer drug tame graft-versus-host disease when steroids fail?
- Genetic hunt for hidden causes of mysterious inflammatory diseases
- New antibody may offer safer shield against transplant complications
- New drug combo aims to tame immune attack after stem cell transplants
- Biopsy tolerance study ends early – what we know
- New drug cocktail aims to stop transplant rejection in blood cancer patients